quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:37:56·43d
ANALYSTRating
Climb Bio Inc. logo

Raymond James initiated coverage on Climb Bio with a new price target

CLYM· Climb Bio Inc.
Health Care
Original source

Companies

  • CLYM
    Climb Bio Inc.
    Health Care

Recent analyst ratings

  • Apr 15UpdateMizuho$18.00
  • Mar 24UpdateB. Riley Securities$26.00
  • Mar 18UpdateTruist$17.00
  • Mar 11UpdateRaymond James$25.00
  • Mar 5UpdateWedbush$12.00
  • Feb 13UpdatePiper Sandler$23.00

Related

  • ANALYST8d
    Mizuho initiated coverage on Climb Bio with a new price target
  • SEC13d
    SEC Form PRE 14A filed by Climb Bio Inc.
  • PR16d
    Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
  • PR17d
    Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
  • SEC20d
    SEC Form 8-K filed by Climb Bio Inc.
  • ANALYST30d
    B. Riley Securities initiated coverage on Climb Bio with a new price target
  • ANALYST36d
    Truist initiated coverage on Climb Bio with a new price target
  • ANALYST49d
    Wedbush initiated coverage on Climb Bio with a new price target
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022